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Uptakecharacterized by the aggregation and subsequent deposition of misfolded β-
amyloid (Aβ) peptide. Previous studies show that aggregated Aβ is more toxic in oligomeric than in ﬁbrillar
form, and that each aggregation form activates speciﬁc molecular pathways in the cell. We hypothesize that
these differences between oligomers and ﬁbrils are related to their different accessibility to the intracellular
space. To this end we used ﬂuorescently labelled Aβ1–42 and demonstrate that Aβ1–42 oligomers readily enter
both HeLa and differentiated SK N SH cells whereas ﬁbrillar Aβ1–42 is not internalized. Oligomeric Aβ1–42 is
internalized by an endocytic process and is transported to the lysosomes. Inhibition of uptake speciﬁcally
inhibits oligomer but not ﬁbril toxicity. Our study indicates that selective uptake of oligomers is a
determinant of oligomer speciﬁc Aβ toxicity.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionOne of the most prominent neuropathological hallmarks in brains
of Alzheimer's disease (AD) patients is the deposition of senile
plaques, extracellular lesions primarily composed of β-amyloid (Aβ).
Aβ is a 40 or 42 amino acid peptide derived from the amyloid
precursor protein (APP) by proteolytic processing. Genetic and
neuropathological studies provide strong evidence for a central role
of Aβ in the pathogenesis of AD [1–3].
One of the main questions still under debate concerning Aβ
toxicity is the (sub-) cellular localization of action. Aβ is secreted into
the extracellular space and ﬁnally deposited in the amyloid plaques in
AD brain. Moreover, Aβ is toxic to various cell types in culture when
applied extracellularly [4–6]. This provides strong evidence for Aβ
exerting its toxic action from the outside of the cell. In addition to the
deposition of Aβ peptides into extracellular plaques there is a large
number of studies now providing evidence for the presence of Aβ
within neurons on post-mortem AD and transgenic mouse brains (as
reviewed in [7,8]). Aβ is produced intracellularly in a variety of
subcellular compartments, including the endoplasmic reticulum (ER),
the Golgi apparatus and lysosomes [9–12]. A triple transgenic AD
mouse model (3xTg) was established that displays cognitive impair-
ments before plaque formation [13]. Here, deﬁcits in synapticeurogenetics Laboratory, P.O.
: +31 20 5664959; fax: +31 20
.
l rights reserved.plasticity, learning, and memory appear to be induced by the buildup
of intraneuronal Aβ. Anti-Aβ immunization results in clearance of
extracellular Aβ before intracellular Aβ in these mice. After removal of
the antibody, the intraneuronal accumulation of Aβ reappears before
the extracellular Aβ deposits [14], indicating a dynamic exchange
between the intra- and extracellular Aβ pools. These studies
demonstrate the importance of intracellular Aβ in the pathogenesis
of AD, however, the respective contribution of extracellular and
intracellular Aβ in AD disease progression is still elusive. In addition, it
is unknown whether intraneuronal Aβ originates from retention and
subsequent aggregation of intracellularly generated Aβ or from
re uptake of extracellular Aβ.
Another major issue in the toxicity of Aβ is the pathophysiolo-
gical role of the different aggregation species of Aβ. The Aβ peptide
can exist in diverse assembly states [15]. Apart from the monomeric
state and the ﬁbrillar end-stage, different intermediate species such
as low molecular weight oligomers (like dimers and trimers), larger
more globular oligomers (Aβ-derived diffusible ligands) and proto-
ﬁbrils have been reported. In vitro, both oligomeric as well as
ﬁbrillar preparations of Aβ induce cell death in virtually any cell
type in culture, but oligomeric preparations do so more potently
[16–18]. These different assembly forms thus greatly differ in their
neurotoxic potential while also the molecular mechanisms they
activate are shown to be speciﬁc for the aggregation state. For
example, small oligomers are shown to cause an impairment of
long term potentiation [19,20] and endoplasmic reticulum (ER)
stress[21], whereas the neuroinﬂammatory response appears to
involve more ﬁbrillar Aβ [22].
The current study addresses the mechanism underlying these
aggregation-state speciﬁc effects. One possible explanation is a
Fig. 1. Preparations enriched in oligomeric (Oligo) and ﬁbrillar (Fibrils) Aβ1–42 were prepared as described in Materials and methods. Representative electron microscope images of
oligomeric (A–B) and ﬁbrillar (C–D) preparations of TMR-labelled Aβ1–42 and Aβ1–42 using negative stain. (Scale bar: 100 nm (A,B); 30 nm (CD)). (E) The width of Aβ ﬁbrils (in nm)
on TEM was measured using the AnalySIS © software. Graph represents the mean±S.D. for n≥30 from two separate experiments. (F–I) The β-sheet content of Aβ ﬁbrils as well as
TMR-labelled Aβ ﬁbrils was analyzed using Congo Red (CR) staining, as described in Materials and methods. Shown are bright light pictures from TAMRA-Aβ ﬁbrils (F) and Aβ (G)
stained with CR and polarized light pictures (H, I) to analyze the CR birefringence, indicative for their β-sheet content. (Scale bars: 100 µm). (J) SK-N-SH cells differentiated for
5 days were treated in the absence (Control) or presence of 10 µM oligomeric or ﬁbrillar TMR-Aβ1–42 or unlabelled Aβ1–42 for 48 h. Viability of the cells was determined by MTT
assay and is depicted as percentage of control. The graph represents the mean±S.D. for n=6 from triplicate wells from two independent experiments. *pb0.05; **pb0.001
(Student's t-test).
524 S.M. Chafekar et al. / Biochimica et Biophysica Acta 1782 (2008) 523–531differential accessibility of different aggregation states to the intracellular
space of the cell. We show selective uptake of oligomers in different cell
types. Preventing oligomeric Aβ fromentering the cell reduces its toxicity
whereas the toxicity of extracellular located ﬁbrils is not affected. Our
study thus indicates that selectiveuptake contributes tooligomer-speciﬁc
toxicity.
2. Materials and methods
2.1. Antibodies and reagents
Cell culture reagents were purchased from Gibco BRL (Gaithers-
burg, MD, USA). Synthetic Aβ1–42 and TMR labelled Aβ1–42 peptide
was purchased from Anaspec (San Jose, CA, USA). Vectashield was
from Vector Laboratories (Burlingame, CA, USA). Rabbit anti Calnexin
antibody was from Calbiochem (San Diego, CA, USA). Alexa-488
labelled Transferrin (Tfn) and Lysotracker Green was from Molecular
Probes (Leiden, The Netherlands). All other chemicals were from
Sigma (St Louis, MO, USA).
2.2. Cell culture
SK N SH human neuroblastoma cells and HeLa cells were main-
tained in DMEM supplemented with 10% foetal calf serum (FCS),
100 U/ml penicillin, 100 μg/ml streptomycin and 300 μg/ml glutamine.
For use in experiments SK-N-SH human neuroblastoma cells were
differentiated for 5 days using cell culture medium supplemented
with 10 μM Retinoic Acid.2.3. Peptide solubilization and aggregation
Aβ1–42 preparations enriched in oligomers and ﬁbrils were obtained
essentially as described in [21]. For the experiments conducted with
TMR-Aβ, unlabelled Aβ1–42 (in HFIP) was spiked with TMR-labelled Aβ1–
42 (in HFIP) at a ratio of 1:2 (TMR-Aβ:Aβ). This mixture was evaporated
using a Speedvac and subsequently used for preparing TMR-oligomers
and TMR-ﬁbrils applying the same procedure as described above. Aβ
treatments were performed in cell culture mediumwithout phenol red.
2.4. Congo Red staining
Aβ preparations were spotted on a cover slip as a 5 μl droplet and
left to dry. The dried specimenwas subsequently ﬁxed with methanol
(−20 °C) for 2min and again left to dry. Then the samples were stained
for 5 minwith Congo Red (0.5 % in PBS/0.01% NaOH), washed with PBS
and left to dry. Then the coverslips were mounted in Vectashield
before analysis on a Zeiss light-microscope equipped with a polariza-
tion ﬁlter to analyze the Congo Red birefringence.
2.5. Electron microscopy
Aβ1–42 preparations were adsorbed onto formvar-coated 300-
mesh copper grids for 5 min and excess ﬂuid was ﬁltered off.
Subsequently, the samples were stained with 1% uranyl acetate for
5 min, excess ﬂuid was ﬁltered off and the grids were analyzed with a
Philips EM-420 transmission electron microscope operated at 100 kV.
The grids were thoroughly examined to get an overall evaluation of
Fig. 2. Aggregation state dependent internalization of Aβ1–42. Shown are confocal images from HeLa cells (A, C, E, G) and differentiated SK-N-SH cells (B, D, F, H) treated with either
10 μM oligomeric preparations of TMR-Aβ1–42 for 15 15 min (A, B) or 60 60 min (E, F) or 10 μM ﬁbrillar preparations for 15 15 min (C, D) or 60 60 min (G, H). After ﬁxation, cells were
counterstained with DAPI (blue in A, C) or a Calnexin antibody (green in B, D–H). Asterisks indicate TMR-Aβ1–42 in the oligomeric preparation not internalized by the cells. Scale bar:
8 μm. (I) HeLa cells and differentiated SK-N-SH cells were treated with 10 μM TMRμAβ1–42 oligomers or ﬁbrils for 15 15 min. For quantitative analysis of the HeLa cells 12 confocal
images from 3–4 independent experiments (N100 cells in total) were counted. For quantitative analysis of the SK-N-SH cells 18–25 confocal images from 7–9 independent
experiments (N200 cells in total) were counted. The graph represents the mean±S.D. from these experiments, the count for uptake of ﬁbrillar Aβ1–42 in HeLa cells was 0; ⁎pb0.001
(Student's t-test).
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the diameters of the ﬁbrils on the EM pictures were measured.
2.6. MTT assay
The cytotoxicity of the Aβ1–42 preparations was assessed by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay. Differentiated SK-N-SH or HeLa cells were incubated with
10 μM oligomeric or ﬁbrillar TMR-Aβ1–42 or unlabelled Aβ1–42
preparations for the indicated times. Following the treatments, cells
were incubated with MTT (0.25 25 mg/ml) for 2 h at 37 °C and the
formazan salt generated by viable cells as a result of conversion of
MTT was dissolved in DMSO and the absorbance was measured at
570 570 nm. In some experiments, HeLa cells and differentiated SK-
N-SH cell were incubated for 30 30 min with 5 5 mM and 1 1 mM
methyl-β-cyclo-dextrin (MβCD), respectively, prior to Aβ1–42 treat-
ment. Experiments were performed at least twice, in triplicate.
2.7. Confocal and immunoﬂuorescence microscopy
Uptake of Aβ and the subcellular localization of Aβ was assessed
by confocal microscopy, using a Leica TCS-SP2 mounted on aninverted microscope (Leica, Heidelberg, Germany) or by immuno-
ﬂuorescence microscopy (Olympus AH3 Vanox) both equipped with
a digital CCD camera. Differentiated neuroblastoma SK-N-SH cells
and HeLa cells were grown on non-coated sterile glass coverslips.
Cells were treated with 10 μM oligomeric or ﬁbrillar TMR-labelled
Aβ1–42 for 15 min. To study the involvement of endocytosis in Aβ
uptake, cells were co incubated with TMR Aβ and Alexa488 labelled
Tfn. Therefore cells were incubated for 30 min with serum-free
medium to deplete the cells from Tfn normally present in serum-
containing medium, prior to co-incubation with Aβ and the
ﬂuorescent Tfn-probe for 15 min. For endocytosis inhibitor experi-
ments HeLa and differentiated SK-N-SH cells were pre treated with
5 mM and 1 mM MβCD, respectively, for 30 min. Subsequently, the
MβCD was washed away and the cells were incubated in serum free
medium for 30 min followed by 15 min incubation with Alexa488-
labelled Tfn (40 μg/ml in serum free medium). Then the cells were
washed twice with cell culture medium, ﬁxed with 4% paraformal-
dehyde for 20 min at room temperature and were incubated with
DAPI and mounted in Vectashield, in case of counterstaining with
calnexin, after permeabilizion with 0.05% saponin in PBS, and
primary and secondary antibody incubations in 0.05% saponin/
1.0 % BSA in PBS.
Fig. 3. Aβ1–42 oligomers are internalized via endocytosis. Differentiated SK-N-SH cells or HeLa cells were co incubated with 10 μM oligomeric TMR-Aβ1–42 and 40 μg/ml Alexa488-Tfn
for different times. (A, B) Confocal images fromHeLa (A) and differentiated SK-N-SH (B) cells treated with oligomeric preparations of TMR-Aβ1–42 for 2min. TMR-Aβ1–42 oligomers are
not internalized after 2min. (C–H) Confocal images fromHeLa cells (C–E) and differentiated SK-N-SH (F–H) treated with TMR-Aβ1–42 oligomers (C, F) in presence of Alexa-488-Tfn (D,
G) for 15 15 min. Yellow signal (arrows) in the overlay pictures (E, H) shows partial co-localization of Aβ with endosomes. TMR-Aβ1–42oligomers are internalized after 15 15 min.
Asterisks indicate larger aggregates in the oligomeric preparation not internalized by the cells. Scale bar: 5 μm.
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we used Lysotracker Green for ﬂuorescent labelling of lysosomes in
live cells. Cells were incubatedwith TMR-labelled Aβ oligomers for the
indicated times. Subsequently the cells were treated with 50 nM
Lysotracker Green for 5 min. Live cells were imaged on a confocal
microscope using an objective heater (set at 37 °C). All microscopy
experiments have been conducted at least twice with different Aβ
preparations.
All microscopy experiments have been conducted at least twice
with different Aβ preparations.
3. Results
3.1. Structural and biological properties of TMR-Aβ1–42
Previously, it was shown that the N-terminus of Aβ is more
accessible and less involved in ﬁbrillogenesis than other regions of
the sequence [23], thus a ﬂuorescent group at the N-terminus is less
likely to interfere with Aβ aggregation than a ﬂuorescent group at the
C-terminus. Therefore we used Aβ1–42 that was N-terminally labelled
with the red ﬂuorophore tetramethylrhodamine (TMR-Aβ1–42) to
make oligomer- and ﬁbril-enriched preparations. TMR-Aβ1–42 was
mixed with 2 molar equivalents of unlabelled Aβ1–42 to minimize
possible interference of the ﬂuorophore with aggregation whilst
retaining sufﬁcient ﬂuorescent signal. This mixture is used as TMR-
Aβ1–42 throughout the experiments.
To characterize the structural and biological features of TMR-Aβ1–42,
the aggregation and toxic properties were compared to those ofunlabelled Aβ1–42. Fibrillar and oligomeric preparations of both TMR-
Aβ1–42 as well as unlabelled Aβ1–42 were analyzed using negative stain
on transmission electron microscopy (TEM, Fig. 1A–D). Both types of
oligomers appeared as small globular structures (with an average
diameter of approximately 5 5 nm) on electron micrographs, in good
accordancewith the size reported by others using a similar protocol for
oligomer preparation [16,17,24,25]. In the ﬁbrillar preparations, both
TMR-Aβ1–42 and unlabelled ﬁbrils showed long threads measuring
N1 μm in length, in line with reported lengths for Aβ ﬁbrils [6,16,17,26].
In addition, the diameter of the labelled and unlabelled ﬁbrils as
measured on EM showed no signiﬁcant difference (7.4±1.41 and 7.6±
1.45 45 nm, respectively, Fig.1E) and are in linewith the reportedwidth
of Aβ ﬁbrils [6,16,17,26]. EM analysis thus indicates that the ﬂuorescent
group does not interfere with the ultrastructure of Aβ aggregates. To
obtain information about the β-sheet content of the ﬁbrils, Congo Red
(CR) staining was performed. Both ﬁbril types showed CR binding (Fig.
1F, G) as well as birefringence under polarized light (Fig. 1H, I),
indicating that the TMR group does not interfere with stacking in the
ﬁbrils.
Next we compared the toxic properties of TMR-Aβ1–42 and
unlabelled Aβ1–42 in differentiated SK-N-SH cells. The decrease in
viability of SK-N-SH cells caused by ﬁbrillar TMR-Aβ1–42 (82.3±9.2%)
and unlabelled ﬁbrils (85.4±5.2%) was not signiﬁcantly different.
Although the decrease in viability of SK-N-SH caused by 10 μM
oligomeric TMR-Aβ1–42 (62.3±3.5%) is slightly lower compared to
10 μM unlabelled oligomers (57.3±2.8%), the differential toxicity
between oligomeric and ﬁbrillar Aβ1–42 that was reported previously
[16,21], is retained (Fig. 1J). Based on the combination of structural
Fig. 4. Internalized Aβ1–42 oligomers is targeted to lysosomes. HeLa cells (A–C, G) and
differentiated SK-N-SH cells (D–F, H) were treatedwith 10 μMTMR-Aβ1–42 oligomers for
1 h (A–F) or 4 h (G–H) and subsequently incubated with 50 nM Lysotracker (LT) Green.
Merged confocal images (C, F, G, H) present TMR-Aβ1–42oligomers in red, LT in green
and co-localization of Aβ oligomers with lysosomes in yellow (arrows). Scale bar: 10 μm.
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TMR-labelled Aβ1–42 have similar structural and toxic properties as
unlabelled Aβ1–42. Therefore TMR-labelled Aβ1–42 provides a valid
model to study aggregation state speciﬁc effects on the subcellular
localization of Aβ1–42.
3.2. Aggregation state speciﬁc uptake of Aβ1–42
To investigatewhetheroligomeric andﬁbrillarAβ1–42 aredifferentially
internalized, cells were treated for 15 15 min with either TMR-oligomers
or TMR ﬁbrils. After treatment the cells were ﬁxed and counterstained
with anti-Calnexin (to visualize the ER) or DAPI (to label the nucleus).We
used HeLa cells and differentiated SK-N-SH cells, the latter to provide a
moreneuronalmodel ofnon dividing cells. In cells treatedwitholigomers,
intracellular red spots are observed distributed throughout the cell body
of both HeLa and SK-N-SH cells after 15 15 min, indicating that the
oligomeric Aβ1–42 is internalized (Fig. 2A, B). In contrast, in cells treated
with TMR-ﬁbrils, all ﬂuorescent signals are located at the cell surface (Fig.
2C, D). This indicates speciﬁc uptake of oligomeric Aβ in both cell types.
Uptake of oligomeric Aβ is not a chance event, as it observed in essentiallyevery cell (Fig. 2I). In SK-N-SH cells treated with Aβ1–42 oligomers, 86.0
±11.3% internalized Aβ, whereas only 6.1±9.0 % of the cells treated with
Aβ1–42 ﬁbrils showed the presence of Aβ inside the cell. The difference in
the internalization of ﬁbrils and oligomers is even more pronounced in
Hela cells. Whereas not a single Hela cell detectably internalizes ﬁbrillar
Aβ1–42, virtuallyall cells (99.0±3.6%) internalizeAβ1–42oligomers (Fig. 2I).
Some of the oligomeric material appears to remain outside the cell
(Fig. 2A, indicated by asterisks throughout the ﬁgures) and is also
observed at later time points (e.g. Fig. 2E and F) This material is often
localized at or close to the plasmamembrane and is larger in size than the
internalized Aβ and may represent a larger aggregated form. Our results
show that both cell types internalize Aβ oligomers, whereas ﬁbrillar Aβ is
located only at the cell surface. After prolonging the incubation time of
TMR-labelledﬁbrils up to anhour, still no intracellularﬂuorescent signal is
observed, whereas the TMR oligomers are abundantly present intracellu-
larly (Fig. 2E–H), indicating that the cells are not capable of internalizing
ﬁbrillar Aβ1–42 aggregates.
3.3. Uptake of Aβ1–42 oligomers via endocytosis
To study if the uptake of Aβ oligomers occurs via endocytosis we
used ﬂuorescently labelled transferrin (Alexa-488 Tfn) as a marker for
endocytosis. After depletion of Tfn in serum free cell culture medium,
HeLa and differentiated SK-N-SH cells were co-incubated with TMR-
Aβ oligomers and Alexa488-Tfn in serum-free medium. Although Tfn
has entered the cells after 2 2 min, TMR-labelled oligomers are
localized at the cell surface and are not found in the intracellular space
(Fig. 3A, B). This is still the case at 5 5 min (not shown), but after 15
15 min oligomeric Aβ was observed inside the cell as shown before
(Fig. 2). This internalized Aβ partially co-localizes with Tfn in both cell
types (Fig. 3C–H). This indicates that Aβ is at least partly internalized
by endocytosis in both HeLa and SK-N-SH cells, however, uptake of Aβ
oligomers takes longer than uptake of ﬂuorescent Tfn.
3.4. Aβ1–42 oligomers end up in lysosomes
To determine the subcellular destination of Aβ after uptake, we
performed further co-localizations. We ﬁnd no co-localization of Aβ
with the ER or the Golgi, also not after prolonged incubation up to 4
and 24 h, respectively (not shown). This indicates that following
endocytosis, oligomeric Aβ1–42 is not retrogradely transported to the
compartments of the early secretory pathway. The most likely
candidate for transport from the endosomes is the lysosomal
compartment. Differentiated SK-N-SH and HeLa cells were treated
for the indicated times with TMR-Aβ1–42 oligomers, and subsequently
Lysotracker Greenwas added to visualize lysosomes in living cells on a
confocal microscope. After 1 h we observed partial co-localization of
TMR-labelled oligomers and Lysotracker Green (Fig. 4A–F). After 4 h,
the co-localization of the Aβ1–42 oligomers with Lysotracker is still
observed in both cell types, indicating that Aβ1–42 is not rapidly
degraded in the lysosomes, (Fig. 4G, H). This result suggests that after
endocytosis, Aβ1–42 oligomers are subsequently transported to the
lysosomal compartment.
3.5. Inhibition of Aβ uptake inhibits oligomer speciﬁc toxicity
To test whether selective uptake of oligomers can explain the
higher toxicity of oligomers compared to ﬁbrils, Aβ treatment was
performed in the presence of the general endocytosis inhibitor
methyl-β-cyclodextrin (MβCD). Co-localization with Alexa488-Tfn-
containing endosomes may indicate that Aβ oligomers are inter-
nalized by clathrin-mediated endocytosis (similar to Tfn). It has been
shown previously, however, that molecules that are internalized via
clathrin-independent mechanisms reach the same early and late
endosome as encountered by molecules internalized via clathrin
coated pits [27]. Therefore we used the drug MβCD, which extracts
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clathrin-dependent endocytosis [28–30]. HeLa cells were treated with
10 μM oligomeric or ﬁbrillar Aβ1–42 for 4 h following a pre-treatment
with 5 mM MβCD or vehicle for 30 min. This strongly inhibits theFig. 5. Uptake of Aβ1–42 oligomers contributes to Aβ oligomer speciﬁc toxicity in HeLa
cells. HeLa cells were treated with 40 μg/ml Alexa488-Tfn or 10 μMTMR-Aβ1–42oligomers
for 15min following a pretreatment in absence (A, C, E, G) or presence (B, D, F, H) of 5mM
MβCD for 30 min. Immuno ﬂuorescence pictures (A–D) demonstrating inhibition of
endocytosis of Alexa488-Tfn after MβCD treatment and confocal pictures (E–H) showing
inhibition of uptake of TMR-Aβ1–42 oligomers (insets show nuclei of HeLa cells stained
with DAPI) Asterisks indicate larger aggregates in the oligomeric preparation not
internalized by the cells. Scale bars: 10 μm. (I) HeLa cells were treated with 10 μM Aβ
oligomers or ﬁbrils for 4 h following a pre-treatment in presence or absence of 5 mM
MβCD for 30 min. Shown is a representative graph of an MTT assay. Viability (mean±S.D.
from n=3) is depicted as percentage of cells without Aβ. Statistically signiﬁcant
differences (Student's t-test) are indicated.
Fig. 6. Uptake of Aβ1–42 oligomers contributes to Aβ oligomer speciﬁc toxicity in SK-N-
SH cells. Differentiated SK-N-SH cells were treated with 40 μg/ml Alexa488-Tfn or 10 μM
TMR-Aβ1–42 oligomers for 15min following a pretreatment in absence (A, C) or presence
(B, D) of 1 mM MβCD for 30 min. Immuno ﬂuorescence pictures (A, B) and confocal
pictures (C, D) demonstrate inhibition of endocytosis of Alexa488-Tfn and uptake of
TMR-Aβ1–42 oligomers by MβCD treatment, respectively. Cells are counterstained with
DAPI (blue). Scale bars: 10 μm. (E) Differentiated SK-N-SH cells were treated with 10 μM
Aβ oligomers or ﬁbrils for 4 h following a pre treatment in presence or absence of 1 mM
MβCD for 30min. Shown is a representative graph of anMTTassay. Viability (mean±S.D.
from n=3) is depicted as percentage of cells without Aβ. Statistically signiﬁcant
differences (Student's t-test) are indicated.uptake of ﬂuorescent Tfn, indicating a near complete inhibition of
endocytosis (Fig. 5A–D). In the same experimental set up, Aβ uptake is
nearly abolished and is found at the plasma membrane (Fig. 5E–H).
Using the MTT viability assay, the effect of inhibition of uptake on Aβ
toxicity was analysed. In absence of MβCD a signiﬁcant difference in
toxicity of oligomers compared to ﬁbrils (Fig. 5I, viability 74% and 84%,
respectively, pb0.001) is observed, although less pronounced than in
the differentiated SK-N-SH cells (Fig. 1J). We ﬁnd that MβCD
pretreatment increases the viability of cells treated with Aβ oligomers
to 85%, whereas the viability of ﬁbril treated cells is unaffected (Fig.
5I), thereby losing the differential effect on cell viability of oligomers
and ﬁbrils. The SK-N-SH cells do not tolerate this concentration of
MβCD, therefore these cells were treated with a lower concentration
(1 mM). Under these conditions, Tfn uptake is not completely
inhibited (Fig. 6A, B), but the uptake of Aβ oligomers is strongly
inhibited (Fig. 6C, D), albeit to a lesser extent than in the HeLa cells
with the higher concentration of MβCD that shows stronger inhibition
of endocytosis altogether. In the differentiated SK-N-SH as well, MβCD
signiﬁcantly reduces the toxicity of oligomeric Aβ (viability from 63 %
to 74 % pb0.001), but does not affect the viability of cells treated with
ﬁbrillar Aβ (Fig. 6E).
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In the present study we investigated whether different accessi-
bility to the intracellular space can underlie the differential effects of
oligomeric and ﬁbrillar Aβ1–42 on cellular toxicity. To study interac-
tions of Aβ oligomers and ﬁbrils with cells, we used N-terminally
TMR-labelled Aβ to generate preparations enriched in oligomeric or
ﬁbrillar Aβ using an established protocol [16,18,21]. Our data
corroborate other studies where different ﬂuorophores at the N-
terminus of Aβ also showed little effect on the amyloidogenic
properties of Aβ [31–33]. We show no effect of the ﬂuorophore on
oligomer or ﬁbril morphology nor on the ability to form β-sheets. In
addition our data show that the ﬂuorophore does not affect the
difference in toxicity between oligomeric and ﬁbrillar preparations.
Therefore we consider the TMR-Aβ1–42 a valid model to study
aggregation-state speciﬁc effects of Aβ1–42.
Both in HeLa and differentiated SK-N-SH cells, we found that
oligomeric TMR-Aβ1–42 is internalized whereas ﬁbrillar TMR-Aβ1–42
remains outside, even after prolonged incubation. We ﬁnd similar
results in HEK293 cells and MelJuSo cells (data not shown). This
indicates that the aggregation state dependent uptake is not cell-type
speciﬁc, although phagocytic cells like microglia and macrophages,
have been shown to be able to phagocytose ﬁbrillar Aβ [34,35]. It is
possible that the presence of Aβ in the relatively compact ﬁbrillar
structure precludes exposure of amino acids required for interaction
with a speciﬁc receptor. Another likely explanation for the aggregation
state dependent uptake of Aβmay be the 3-dimensional characteristics
of the aggregate. Uptake of particles into mammalian cells is size and
shape dependent as was determined using gold nanoparticles. Most
efﬁcient uptake was found with small (50 nm), spherical gold
nanoparticles. Increasing particle size greatly reduces its uptake.
Uptake of rod-shaped particles also occurs at a much lower rate
[36,37]. Oligomers are spherical Aβ structures with an average z height
and diameter of 5 nm [4] and thus have structural features that
facilitate uptake in the cell. In contrast,ﬁbrils are rod-shaped structures
over 1 μm in length with a diameter of 7 nm, structural properties not
compatible with easy internalization. Not all Aβ in the oligomer
preparation is internalized. In oligomer-treated samples, particles are
observed on the outside of the cell membrane that are typically much
larger than the internalized material. Since Aβ aggregation has been
shown to occur very rapidly in the presence of lipid bilayers, such as
lipid rafts [38–42], this material may represent larger aggregates
formed during the incubation with the cells, that can no longer be
internalized. These larger aggregates are most likely not ﬁbrils, since it
was shown previously that oligomeric preparations similar to ours do
not form ﬁbrils for several days even not during incubation at 37 °C [4].
To study if oligomers are speciﬁcally internalized by the cell via
endocytosis, cells were co-incubated with TMR-oligomers in presence
of Alexa488-Tfn. Transferrin binds to the transferrin receptor and this
complex is internalized via receptor mediated endocytosis. Both in
HeLa cells and differentiated SK-N-SH cells Aβ oligomers were
internalized at least in part via endocytosis, as shown by the co-
localization of TMR-Aβ oligomers and Alexa488-Tfn. The Tfn-probe
only labels early and recycling endosomes, since the Tfn receptor/Tfn
complex is recycled back to the plasma membrane [43]. Therefore the
Aβ not co-localizing with Tfn is most likely present in late endosomes
or other compartments beyond early endosomes. Alternatively, Aβ
oligomers are in an endosome that does not contain Alexa488-Tfn.
Partial co-localization may be caused by differential endocytic sorting
of Tfn, that is recycled via recycling endosomes and Aβ, that is
transported to the lysosomal compartment. Internalized LDL (low-
density lipoprotein), that is (like TMR-Aβ oligomers) transported to
the lysosomes also shows only partial co-localization with Tfn [44].
Pre-treatment with an endocytosis inhibitor, MβCD, strongly inhibits
both Tfn and Aβ uptake, conﬁrming endocytosis as mechanism of Aβ
uptake. Endocytosis of Aβ oligomers occurs at a slower rate (15 min)than endocytosis of Tfn (b2 min). This is most likely due to the fact
that Tfn, has a highly speciﬁc receptor (Tfn-receptor) to which it binds
very efﬁciently, leading to fast uptake by the cell. The binding of Aβ to
the plasma membrane has been studied previously, and a number of
candidate Aβ-binding receptors have been identiﬁed (such as FPRL1-,
RAGE-, NMDA- andLRP-receptors [8]. However, noneof these receptors
is designed for the uptake of Aβ oligomers and their afﬁnity for Aβmay
be lower than for their natural ligands. For example, binding of Aβ to
the alpha7 nicotinic acetylcholine receptor results in internalization
and accumulation of Aβ intracellularly [45,46]. Aβ internalization via
the alpha7 nicotinic receptor occurs after 30 min [45], whereas its
natural ligand nicotine is endocytosed within 5 min [47].
Not surprisingly we found Aβ1–42 oligomers clearly present in
lysosomes. Increased accumulation of Aβ1–42 oligomers in the
lysosomal compartment after longer incubation, suggests that its
presence in the lysosome is involved in toxicity. This is in accordance
with other studies showing presence of Aβ1–42 in the endosomal/
lysosomal system [48–50]. Aβ1–42 is poorly degraded by lysosomes
[51] and its accumulation in lysosomes of cultured neurons causes
leakage of lysosomal enzymes [52] and can ultimately lead to
programmed cell death [53]. This may explain the toxicity that we
observe after endocytosis and subsequent accumulation in the
lysosomes and may be one of the pathways leading to neurodegen-
eration in AD. This is supported by data from post mortem brain
material: neurons in vulnerable brain regions in AD patients show an
increased number of structurally abnormal endosomes and lyso-
somes, endosome enlargement, and an increase in expression of
lysosomal hydrolases [51,54,55]. In addition to these direct toxic
effects, the endosomal–lysosomal pathway has been identiﬁed as
particularly important to processing of the amyloid precursor protein
(APP) [56–60]. In case the endosomal–lysosomal compartment is
compromised by Aβ this can lead to redistribution of APP and its
processing activities and thus increase Aβ production. Endosomal/
lysosomal abnormalities are therefore believed to contribute sig-
niﬁcantly to Aβ overproduction [57,61,62] and neuronal dysfunction
[9]. The presence of Aβ1–42 in the endosomal–lysosomal system can
thus lead to an autocatalytic cycle that results in an increase in the
levels of Aβ, that in turn can aggregate and is poorly degraded [63].
To determine if there is a connection between subcellular
localization and Aβ toxicity, toxicity of oligomers in absence or
presence of MβCD was compared. Inhibition of uptake reduces the
toxicity of oligomers in both HeLa as well as differentiated SK-N-SH
cells. The toxicity of ﬁbrillar Aβ1–42 is not affected, which is in good
accordance with the lack of internalization of ﬁbrils. In the
differentiated SK-N-SH cells a total block of uptake was not tolerated,
but even incomplete inhibition relieved oligomer-speciﬁc toxicity.
Interestingly, in HeLa cells, the MβCD treatment reduced the oligomer
toxicity to a level similar to that of ﬁbrils. This indicates that Aβ1–42
can exert toxicity from the outside of the cell (i.e. the toxicity of ﬁbrils
and the residual toxicity of oligomers present at or close to the plasma
membrane, after inhibition of uptake), but that for the speciﬁc toxicity
of oligomeric Aβ1–42 uptake is required. A recent study by Bateman et
al. shows that a cell line that is resistant to Aβ cytotoxicity, the
non neuronal human lymphoma cell line U937 [64], does not bind
Aβ1–42 [33]. This suggests that at least an interaction of Aβ with the
cell membrane is required to confer toxicity on mammalian cells. An
alternative explanation for the protective effect of MβCD could be that
once depleted of cholesterol, membranes are less susceptible to
oligomers. Conﬂicting results have been reported so far on the effects
of cholesterol enrichment and depletion from the plasma membrane
on Aβ toxicity and membrane binding [38,65–69]. The experimental
design in these studies was not optimal to fully explore Aβ toxicity
following MβCD treatment, because cell viability was determined
after 24 h or longer, giving the cell time to replenish the cholesterol
levels of the membrane. This makes it difﬁcult to interpret these
results on the role of cholesterol on Aβ toxicity. Regardless, decreased
530 S.M. Chafekar et al. / Biochimica et Biophysica Acta 1782 (2008) 523–531membrane binding does not provide a likely explanation for the
protective effect we observe of MβCD treatment, since we ﬁnd that
the majority of Aβ oligomers is membrane associated after pre-
treatment with MβCD.
There is a large body of evidence demonstrating that Aβ
accumulates intracellularly and that Aβ accumulation inside neurons
is detrimental to a range of cellular processes [8]. It is unclear whether
the intracellular Aβ accumulates because part of the intracellularly
generated Aβ is not secreted, or whether it derives from re-uptake of
secreted Aβ. Several studies indicate that intra- and extracellular pools
are in equilibrium, as clearance of extracellular Aβ depletes the
intracellular pool as well [70]. Therefore, targeting of the more easily
accessible extracellular Aβ is still a promising option for therapeutic
intervention. We report here that selective uptake of oligomeric Aβ
contributes to toxicity. Our study indicates that prevention of the
internalization of oligomeric Aβmay be an attractive additional aim in
therapeutic strategies targeting extracellular Aβ.
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